|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/20 89bio, Inc. 10-Q 9/30/20 52:6.8M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.18M
2: EX-10.1 Material Contract HTML 28K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
5: EX-32 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 73K
13: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 78K
14: R3 Condensed Consolidated Statements of Operations HTML 68K
and Comprehensive Loss (Unaudited)
15: R4 Condensed Consolidated Statements of Convertible HTML 106K
Preferred Stock and Stockholders' Equity Deficit
(Unaudited)
16: R5 Condensed Consolidated Statements of Convertible HTML 22K
Preferred Stock and Stockholders' Equity Deficit
(Unaudited) (Parenthetical)
17: R6 Condensed Consolidated Statements of Cash Flows HTML 104K
(Unaudited)
18: R7 Organization and Basis of Presentation HTML 25K
19: R8 Summary of Significant Accounting Policies HTML 35K
20: R9 Fair Value Measurements HTML 161K
21: R10 Consolidated Balance Sheet Components HTML 42K
22: R11 Commitments and Contingencies HTML 33K
23: R12 Term Loan HTML 22K
24: R13 Stockholders' Equity HTML 148K
25: R14 Net Loss Per Share HTML 40K
26: R15 Related Party Transactions HTML 21K
27: R16 Summary of Significant Accounting Policies HTML 57K
(Policies)
28: R17 Fair Value Measurements (Tables) HTML 166K
29: R18 Consolidated Balance Sheet Components (Tables) HTML 41K
30: R19 Commitments and Contingencies (Tables) HTML 29K
31: R20 Stockholders' Equity (Tables) HTML 148K
32: R21 Net Loss Per Share (Tables) HTML 39K
33: R22 Organization and Basis of Presentation - HTML 58K
Additional Information (Details)
34: R23 Summary of Significant Accounting Policies - HTML 48K
Additional Information (Details)
35: R24 Fair Value Measurements - Summary of Financial HTML 58K
Assets Measured at Fair Value on Recurring Basis
(Details)
36: R25 Fair Value Measurements - Schedule of Contractual HTML 25K
Maturities of Available-for-Sale Securities
(Details)
37: R26 Fair Value Measurements - Additional Information HTML 24K
(Details)
38: R27 Fair Value Measurements - Summary of Changes in HTML 27K
Fair Value of Level 3 Liability (Details)
39: R28 Fair Value Measurements - Summary of Fair Value HTML 39K
Assumptions (Details)
40: R29 Consolidated Balance Sheet Components - Schedule HTML 29K
of Accrued Expenses (Details)
41: R30 Commitments and Contingencies - Schedule of Future HTML 27K
Minimum Lease Payments Under Non-cancellable
Operating Lease Obligations (Details)
42: R31 Commitments and Contingencies - Additional HTML 41K
Information (Details)
43: R32 Term Loan - Additional Information (Details) HTML 68K
44: R33 Stockholders' Equity - Additional Information HTML 72K
(Details)
45: R34 Stockholders' Equity - Summary of Share-Based HTML 25K
Compensation (Details)
46: R35 Stockholders' Equity - Summary of Estimated Fair HTML 32K
Value of Option Awards Granted Using Black-Scholes
Option-Pricing Model (Details)
47: R36 Stockholders' Equity - Summary of Stock Option HTML 58K
Activity (Details)
48: R37 Net Loss Per Share - Schedule of Outstanding HTML 28K
Potentially Dilutive Securities Excluded From
Calculation of Diluted Net Loss (Details)
49: R38 Related Party Transactions - Additional HTML 25K
Information (Details)
51: XML IDEA XML File -- Filing Summary XML 90K
50: EXCEL IDEA Workbook of Financial Reports XLSX 57K
6: EX-101.INS XBRL Instance -- etnb-20200930 XML 1.29M
8: EX-101.CAL XBRL Calculations -- etnb-20200930_cal XML 105K
9: EX-101.DEF XBRL Definitions -- etnb-20200930_def XML 401K
10: EX-101.LAB XBRL Labels -- etnb-20200930_lab XML 872K
11: EX-101.PRE XBRL Presentations -- etnb-20200930_pre XML 640K
7: EX-101.SCH XBRL Schema -- etnb-20200930 XSD 113K
52: ZIP XBRL Zipped Folder -- 0001564590-20-053677-xbrl Zip 99K
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Ryan Martins, certify that:
|
1. |
I have reviewed this Quarterly Report on Form 10-Q of 89bio, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: |
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
(b) |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
(c) |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
|
5. |
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
Date: November 12, 2020 |
By: |
/s/ Ryan Martins |
|
|
|
Chief Financial Officer |
|
|
|
(principal financial and accounting officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 11/13/20 | None on these Dates | ||
| Filed on: | 11/12/20 | |||
| For Period end: | 9/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/23 89bio, Inc. 10-K 12/31/22 68:14M Donnelley … Solutions/FA 3/24/22 89bio, Inc. 10-K 12/31/21 62:12M ActiveDisclosure/FA 3/25/21 89bio, Inc. 10-K 12/31/20 65:8.8M ActiveDisclosure/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/13/20 89bio, Inc. 8-K:1,2,3,9 4/07/20 3:457K Donnelley … Solutions/FA 11/15/19 89bio, Inc. 8-K:5,9 11/13/19 3:162K Donnelley … Solutions/FA 10/28/19 89bio, Inc. S-1/A 12:6.6M Donnelley … Solutions/FA 10/11/19 89bio, Inc. S-1 19:6.5M Donnelley … Solutions/FA |